Systemic Lupus Erythematosus - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 260 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Systemic Lupus Erythematosus - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Systemic Lupus Erythematosus - Pipeline Review, H2 2014', provides an overview of the Systemic Lupus Erythematosus's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Systemic Lupus Erythematosus and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Systemic Lupus Erythematosus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Systemic Lupus Erythematosus pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Systemic Lupus Erythematosus Overview 10
Therapeutics Development 11
Pipeline Products for Systemic Lupus Erythematosus - Overview 11
Pipeline Products for Systemic Lupus Erythematosus - Comparative Analysis 12
Systemic Lupus Erythematosus - Therapeutics under Development by Companies 13
Systemic Lupus Erythematosus - Therapeutics under Investigation by Universities/Institutes 18
Systemic Lupus Erythematosus - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Systemic Lupus Erythematosus - Products under Development by Companies 23
Systemic Lupus Erythematosus - Products under Investigation by Universities/Institutes 27
Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development 28
F. Hoffmann-La Roche Ltd. 28
Biogen Idec Inc. 29
Amgen Inc. 30
Sanofi 31
Eli Lilly and Company 32
GlaxoSmithKline plc 33
MedImmune, LLC 34
Biotest AG 35
Ablynx NV 36
Novo Nordisk A/S 37
Takeda Pharmaceutical Company Limited 38
Eisai Co., Ltd. 39
Pfizer Inc. 40
UCB S.A. 41
Celgene Corporation 42
XTL Biopharmaceuticals Ltd. 43
Merck KGaA 44
4SC AG 45
Harbor Therapeutics, Inc. 46
Immunomedics, Inc. 47
Idera Pharmaceuticals, Inc. 48
Karo Bio AB 49
Dynavax Technologies Corporation 50
Hansa Medical AB 51
Immupharma Plc 52
Argos Therapeutics, Inc. 53
MacroGenics, Inc. 54
Kineta, Inc. 55
Xencor, Inc. 56
SBI Biotech Co., Ltd. 57
Invion Limited 58
Anthera Pharmaceuticals� Inc. 59
SuppreMol GmbH 60
NasVax Ltd. 61
Lycera Corp. 62
Genosco 63
RedHill Biopharma Ltd. 64
National Pharmaceutical Corp. 65
Resolve Therapeutics, LLC 66
Lead Discovery Center GmbH 67
Genovax S.r.l. 68
MENTRIK Biotech, LLC 69
Avipep Pty Ltd 70
AbbVie Inc. 71
ImmuNext, Inc. 72
Cellular Biomedicine Group, Inc. 73
Medsenic 74
Azano Pharmaceuticals Inc. 75
Systemic Lupus Erythematosus - Therapeutics Assessment 76
Assessment by Monotherapy Products 76
Assessment by Combination Products 77
Assessment by Target 78
Assessment by Mechanism of Action 82
Assessment by Route of Administration 86
Assessment by Molecule Type 88
Drug Profiles 91
forigerimod - Drug Profile 91
tabalumab - Drug Profile 93
belimumab - Drug Profile 95
blisibimod - Drug Profile 98
epratuzumab - Drug Profile 101
atacicept - Drug Profile 106
sifalimumab - Drug Profile 108
PF-04236921 - Drug Profile 110
edratide - Drug Profile 111
ALX-0061 - Drug Profile 112
XmAb-5871 - Drug Profile 114
anifrolumab - Drug Profile 115
INV-103 - Drug Profile 116
SM-101 - Drug Profile 118
CC-220 - Drug Profile 120
RSLV-132 - Drug Profile 122
arsenic trioxide - Drug Profile 123
milatuzumab - Drug Profile 124
IFNa-Kinoid - Drug Profile 126
epratuzumab - Drug Profile 128
AMG-811 - Drug Profile 133
AMG-557 - Drug Profile 134
BT-063 - Drug Profile 136
AGS-009 - Drug Profile 137
CDP-7657 - Drug Profile 138
DV-1179 - Drug Profile 140
CC-292 - Drug Profile 142
venetoclax - Drug Profile 144
NN-8828 - Drug Profile 147
AMG-729 - Drug Profile 149
IMO-8400 - Drug Profile 150
SAR-113244 - Drug Profile 152
PF-04965842 - Drug Profile 153
BIIB-059 - Drug Profile 154
MEDI-4920 - Drug Profile 155
HE-3286 - Drug Profile 156
AMP-110 - Drug Profile 158
Antibody to Inhibit ILT7 for Autoimmune Disorders - Drug Profile 160
TAK-114 - Drug Profile 161
Anti-CD3 Oral Immunotherapy - Drug Profile 163
(rifabutin + clarithromycin + clofazimine) - Drug Profile 165
Leukothera - Drug Profile 167
ShK-186 - Drug Profile 168
MGD-010 - Drug Profile 170
Small Molecule to Inhibit F1F0-ATP Synthase for Autoimmune and Gastrointestinal Disease - Drug Profile 171
Endoglycosidase of Streptococcus pyogenes - Drug Profile 172
GX-101 - Drug Profile 173
E-6446 - Drug Profile 174
Small Molecule to Inhibit RORgammat for CNS, Autoimmune and Gastrointestinal Disorders - Drug Profile 175
Synthetic Peptides for Systemic Lupus Erythematosus - Drug Profile 176
Y-27 - Drug Profile 177
caffeic acid phenethyl ester - Drug Profile 178
RSLV-133 - Drug Profile 180
Human Umbilical Cord Derived Mesenchymal Progenitor Cells - Drug Profile 181
GNKS-356 - Drug Profile 182
NCS-613 - Drug Profile 183
AZ-175 - Drug Profile 184
DCB-3503 - Drug Profile 185
IGM-001 - Drug Profile 186
IIIM1 Peptide - Drug Profile 187
VISTA-Ig - Drug Profile 188
RN-486 - Drug Profile 189
SM-934 - Drug Profile 190
RO-5461111 - Drug Profile 191
AT-791 - Drug Profile 192
Vaccine for Systemic Lupus Erythematosus Vaccine - Drug Profile 193
ABS-11 - Drug Profile 194
BB-004 - Drug Profile 195
Small Molecule to Inhibit SYK for Systemic Lupus Erythematosus - Drug Profile 196
IMP-10 - Drug Profile 197
Cell Therapy for Autoimmune Diseases and GVHD - Drug Profile 198
nPT-mTOR - Drug Profile 200
GLB-333 - Drug Profile 201
AVP-5 - Drug Profile 202
Drug to Target NURR-1 Receptor for Immunology, CNS and Metabolic Disorders - Drug Profile 203
Recombinant Proteins for Systemic Lupus Erythematosus - Drug Profile 204
Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile 205
Y-175L - Drug Profile 206
KY-1015 - Drug Profile 207
ocaratuzumab - Drug Profile 208
Systemic Lupus Erythematosus - Recent Pipeline Updates 210
Systemic Lupus Erythematosus - Dormant Projects 245
Systemic Lupus Erythematosus - Discontinued Products 246
Systemic Lupus Erythematosus - Product Development Milestones 247
Featured News & Press Releases 247
Appendix 253
Methodology 253
Coverage 253
Secondary Research 253
Primary Research 253
Expert Panel Validation 253
Contact Us 254
Disclaimer 254

List of Tables
Number of Products under Development for Systemic Lupus Erythematosus, H2 2014 17
Number of Products under Development for Systemic Lupus Erythematosus - Comparative Analysis, H2 2014 18
Number of Products under Development by Companies, H2 2014 20
Number of Products under Development by Companies, H2 2014 (Contd..1) 21
Number of Products under Development by Companies, H2 2014 (Contd..2) 22
Number of Products under Development by Companies, H2 2014 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H2 2014 24
Comparative Analysis by Late Stage Development, H2 2014 25
Comparative Analysis by Clinical Stage Development, H2 2014 26
Comparative Analysis by Early Stage Development, H2 2014 27
Comparative Analysis by Unknown Stage Development, H2 2014 28
Products under Development by Companies, H2 2014 29
Products under Development by Companies, H2 2014 (Contd..1) 30
Products under Development by Companies, H2 2014 (Contd..2) 31
Products under Development by Companies, H2 2014 (Contd..3) 32
Products under Investigation by Universities/Institutes, H2 2014 33
Systemic Lupus Erythematosus - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 34
Systemic Lupus Erythematosus - Pipeline by Biogen Idec Inc., H2 2014 35
Systemic Lupus Erythematosus - Pipeline by Amgen Inc., H2 2014 36
Systemic Lupus Erythematosus - Pipeline by Sanofi, H2 2014 37
Systemic Lupus Erythematosus - Pipeline by Eli Lilly and Company, H2 2014 38
Systemic Lupus Erythematosus - Pipeline by GlaxoSmithKline plc, H2 2014 39
Systemic Lupus Erythematosus - Pipeline by MedImmune, LLC, H2 2014 40
Systemic Lupus Erythematosus - Pipeline by Biotest AG, H2 2014 41
Systemic Lupus Erythematosus - Pipeline by Ablynx NV, H2 2014 42
Systemic Lupus Erythematosus - Pipeline by Novo Nordisk A/S, H2 2014 43
Systemic Lupus Erythematosus - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 44
Systemic Lupus Erythematosus - Pipeline by Eisai Co., Ltd., H2 2014 45
Systemic Lupus Erythematosus - Pipeline by Pfizer Inc., H2 2014 46
Systemic Lupus Erythematosus - Pipeline by UCB S.A., H2 2014 47
Systemic Lupus Erythematosus - Pipeline by Celgene Corporation, H2 2014 48
Systemic Lupus Erythematosus - Pipeline by XTL Biopharmaceuticals Ltd., H2 2014 49
Systemic Lupus Erythematosus - Pipeline by Merck KGaA, H2 2014 50
Systemic Lupus Erythematosus - Pipeline by 4SC AG, H2 2014 51
Systemic Lupus Erythematosus - Pipeline by Harbor Therapeutics, Inc., H2 2014 52
Systemic Lupus Erythematosus - Pipeline by Immunomedics, Inc., H2 2014 53
Systemic Lupus Erythematosus - Pipeline by Idera Pharmaceuticals, Inc., H2 2014 54
Systemic Lupus Erythematosus - Pipeline by Karo Bio AB, H2 2014 55
Systemic Lupus Erythematosus - Pipeline by Dynavax Technologies Corporation, H2 2014 56
Systemic Lupus Erythematosus - Pipeline by Hansa Medical AB, H2 2014 57
Systemic Lupus Erythematosus - Pipeline by Immupharma Plc, H2 2014 58
Systemic Lupus Erythematosus - Pipeline by Argos Therapeutics, Inc., H2 2014 59
Systemic Lupus Erythematosus - Pipeline by MacroGenics, Inc., H2 2014 60
Systemic Lupus Erythematosus - Pipeline by Kineta, Inc., H2 2014 61
Systemic Lupus Erythematosus - Pipeline by Xencor, Inc., H2 2014 62
Systemic Lupus Erythematosus - Pipeline by SBI Biotech Co., Ltd., H2 2014 63
Systemic Lupus Erythematosus - Pipeline by Invion Limited, H2 2014 64
Systemic Lupus Erythematosus - Pipeline by Anthera Pharmaceuticals� Inc., H2 2014 65
Systemic Lupus Erythematosus - Pipeline by SuppreMol GmbH, H2 2014 66
Systemic Lupus Erythematosus - Pipeline by NasVax Ltd., H2 2014 67
Systemic Lupus Erythematosus - Pipeline by Lycera Corp., H2 2014 68
Systemic Lupus Erythematosus - Pipeline by Genosco, H2 2014 69
Systemic Lupus Erythematosus - Pipeline by RedHill Biopharma Ltd., H2 2014 70
Systemic Lupus Erythematosus - Pipeline by National Pharmaceutical Corp., H2 2014 71
Systemic Lupus Erythematosus - Pipeline by Resolve Therapeutics, LLC, H2 2014 72
Systemic Lupus Erythematosus - Pipeline by Lead Discovery Center GmbH, H2 2014 73
Systemic Lupus Erythematosus - Pipeline by Genovax S.r.l., H2 2014 74
Systemic Lupus Erythematosus - Pipeline by MENTRIK Biotech, LLC, H2 2014 75
Systemic Lupus Erythematosus - Pipeline by Avipep Pty Ltd, H2 2014 76
Systemic Lupus Erythematosus - Pipeline by AbbVie Inc., H2 2014 77
Systemic Lupus Erythematosus - Pipeline by ImmuNext, Inc., H2 2014 78
Systemic Lupus Erythematosus - Pipeline by Cellular Biomedicine Group, Inc., H2 2014 79
Systemic Lupus Erythematosus - Pipeline by Medsenic, H2 2014 80
Systemic Lupus Erythematosus - Pipeline by Azano Pharmaceuticals Inc., H2 2014 81
Assessment by Monotherapy Products, H2 2014 82
Assessment by Combination Products, H2 2014 83
Number of Products by Stage and Target, H2 2014 86
Number of Products by Stage and Mechanism of Action, H2 2014 90
Number of Products by Stage and Route of Administration, H2 2014 93
Number of Products by Stage and Molecule Type, H2 2014 96
Systemic Lupus Erythematosus Therapeutics - Recent Pipeline Updates, H2 2014 216
Systemic Lupus Erythematosus - Dormant Projects, H2 2014 251
Systemic Lupus Erythematosus - Discontinued Products, H2 2014 252